Merck is slated to launch KEYTRUDA QLEX, a novel subcutaneous formulation of pembrolizumab, on September 19, 2025, anticipating a shift in market dynamics by potentially reducing infusion times and altering treatment adherence patterns. This innovation strengthens the manufacturer’s portfolio amid intensifying immunotherapy competition and offers a competitive advantage in the growing segment of at-home injectable biologics.